Navigation Links
ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS
Date:2/3/2009

IRVINE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies for critically ill patients, today announced that it is prepared to respond aggressively to the patent lawsuit brought against it by ZOLL Circulation, Inc., a subsidiary of ZOLL Medical Corporation (Nasdaq: ZOLL). Alsius was sued by ZOLL based on two temperature management patents ZOLL purchased from a defunct competitor of Alsius'. Alsius believes that its patents do not infringe on the ZOLL patents, and that ZOLL's core temperature management patents are invalid. Alsius believes that it retains a dominant patent position in intravascular cooling that, among other things, precludes any competitor from marketing an intravascular cooling catheter for therapeutic hypothermia in patients who have had cardiac arrest or heart attack. ZOLL has not yet sold temperature management products based on ZOLL's patents.

About Alsius Corporation

Alsius, the worldwide leader in intravascular temperature management, develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the largely unmet clinical need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit www.alsius.com.


'/>"/>
SOURCE Alsius Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue
2. Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress
3. Alsius Corporation to Host Third Quarter 2008 Financial Results Conference Call on November 6
4. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
5. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
6. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
7. Alsius Corporation Receives Regulatory Approval in China and Mexico
8. Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
9. Alsius Corporation Announces Program for Early Exercise of Warrants
10. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...The following is an investment opinion release iss... Intellivest Securities Research, Inc., ("ISR") a ...ed a Report on BioClinica, Inc. ( BIOC) which serv...and medical device industries. A primary service ...t medical imaging portions of their submissions re...
(Date:11/29/2009)...ads to more self-defensive finger pointing, study ...s) -- The blame game is a contagious one, a new st..., Researchers found that when people see someone b...nfair accusation, they,re much more likely to enga...rs protecting their egos, we become defensive, too...
(Date:11/28/2009)... Welcome to syngo® .plaza(1), the new...om Siemens Healthcare. As the first Picture Ar...emens where 2D, 3D, and 4D reading come together i... the way multimodality images are read today. Siem...entific Assembly and Annual Meeting of the Radiolo...
(Date:11/27/2009)...re-FirstCall/ -- GSI Group Inc. (Pink Sheets: GSIG...ogy products and semiconductor systems, today anno...eholders has been scheduled for Friday, April 30, ...e announced in due course. As previously announce...Stephen Bershad, a holder of greater than ten perc...
(Date:11/27/2009)...re-USNewswire/ -- Preventing disease is the goal o... year, new vaccines are being added to assist in d...ity for the same period of time? And, if not, when...unity strong? ,, In this month,s issue of Ped...diatrics, Michael Pichichero MD, Director of the R...
Breaking Medicine News(10 mins):Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3
... Patients with rheumatoid arthritis hopes have bee...howed positive results and was safe without any si... Roche Holding AG will file the drug Actemra for r...4519.TO), which is controlled by Roche. Roche owns...
... Civilians in Indonesia's Aceh, which was wracked ...s of mental trauma that could trigger more violenc...e International Organisation for Migration and Har... 39 percent for anxiety. The report sampl...
... Animal rights activists strutted naked through To... boycott of fashion giant Burberry for using fur....p to the Burberry store on the Ginza strip of high...st by People for the Ethical Treatment of Animals,...
... The many Australians taking to the bottle is not ...ed a bottle neck in the health system, overburdene...n the people’s health. Binge drinking has b...the next 20 years. Many Australians will be suffer...
... One of Australia's biggest bread companies is not...brands of bread with folic acid. They are petition...is proposal. The objective of such a proposa... If you ask Ian Greenshields from Goodman Fiel...
... The suspended West Coast Eagles star Ben Cousins ...rents broke the news in March to confirm// that he...evealed that he was under treatment at an overseas...name of the drug that he had been using. Sub...
Other Medicine News:Health News:New Drug for Rheumatoid Arthritis Looks Promising. 2Health News:Indonesia's Acehnese Suffer High Rates of Mental Trauma 2Health News:Cousins Recovering from His Substance Abuse Problem 2
(Date:11/25/2009)..., , WEST PALM BEACH, Fla., Nov. 25 /PRNe...earing impaired Americans, especially the 27 milli...ays may not be all that happy, says audiologist Ci...of HearUSA (Amex: EAR ), one of America,s largest...tudies have linked hearing loss to stress, frustra...
(Date:11/25/2009)..., , BASKING RIDGE, N.J., Nov. 25 /PRNewsw...ny leading the development of antithrombotic aptam...id Mazzo, PhD, CEO and President, will be presenti...nference at the New York Palace Hotel in New York ...:10pm (EST) on Tuesday, December 1 and will includ...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...ive ,, http://www.reportlinker.com/p0164330/...e.html ,, Rising incidence of breast cancer in... principal factor influencing growth in the mammog...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8DATATRAK Signs 6 Year Study with New Device Client 5306 1DATATRAK Signs 6 Year Study with New Device Client 5306 2DATATRAK Signs 6 Year Study with New Device Client 5306 3Curemark Announces Senior Executive Promotions 5301 1Curemark Announces Senior Executive Promotions 5301 2Curemark Announces Senior Executive Promotions 5301 3Early Defibrillator After Heart Attack May Not Pay Off 59091 1Early Defibrillator After Heart Attack May Not Pay Off 59091 2Early Defibrillator After Heart Attack May Not Pay Off 59091 3
...tigational regimen yielded nearly double SVR rate ...eneration HCV protease inhibitor SCH 900518 presen...k, April 23 Schering-Plough Corporation (NYSE: ... SPRINT-1 study showed boceprevir, its investigati...nation with peginterferon alfa-2b and ribavirin, s...
... Continuing Education Online Activity and Podcast ...ril 22 Acute lymphoblastic leukemia (ALL) is a co...cant advances in the treatment of pediatric patien...ealthcare professionals who treat adult patients w... the multitude of factors affecting management opt...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions 2
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: